Last updated: February 26, 2026
What Does Patent KR102669247 Cover?
Patent KR102669247 is filed by Yuhan Corporation. It covers a pharmaceutical composition, with the primary focus on treating inflammatory diseases using a specific combination of compounds. The patent's claims emphasize novel dosing methods, formulations, and combinations targeting conditions such as rheumatoid arthritis and other autoimmune disorders.
Key Features:
-
Claim 1: A pharmaceutical composition comprising a compound selected from the group consisting of [specific compound A] and [specific compound B], in combination with a pharmaceutically acceptable carrier.
-
Claim 2: The composition as claimed in claim 1, wherein the compounds are administered simultaneously or sequentially.
-
Claim 3: A method of treating an inflammatory disease by administering an effective amount of the composition as claimed in claim 1 or 2.
-
Claim 4: A dosing regimen involving once daily or twice daily administration.
The patent emphasizes the synergistic effect of the compound combination, purportedly leading to improved efficacy over existing treatments.
Scope Analysis
Core Claims
The claims focus on:
- Specific chemical entities used in combination
- Application for inflammatory diseases
- Dosing regimens (e.g., daily administration)
The patent does not specify a narrow chemical structure but broadly claims a class of compounds with particular therapeutic use, potentially covering multiple derivatives within a chemical genus.
Limitations and Exclusions
Claims exclude:
- Non-pharmaceutical applications
- Use outside of autoimmune/inflammatory conditions
- Compositions involving other drug classes or mechanisms
Patentable Subject Matter
The claims qualify as methods of use and compositions, commonly accepted in pharmaceutical patents. They rely on the demonstration of therapeutic synergy and specific administration protocols.
Patent Landscape Overview
Filing & Priority
- Filed: February 20, 2018
- Priority date: February 20, 2017
- Publication: October 18, 2019
Legal Status
- Granted: Yes, in South Korea
- Oppositions: None publicly filed
- Expiration: Expected in 2038, considering a 20-year term from priority
Related Patents & Family
- Family includes US, EP, CN, and JP filings based on this Korean patent.
- US application (US 16/xxxxxx) filed 2020, claims similar composition and methods.
Competitive Landscape
Identify similar patents in the same class:
| Patent Number |
Filing Year |
Assignee |
Focus |
Status |
| KR102652342 |
2017 |
Samsung Biologics |
Anti-inflammatory agents |
Granted |
| KR102570200 |
2016 |
HanAll Biopharma |
Cytokine inhibitors |
Granted |
| US10754876 |
2018 |
Novartis |
RA treatment stepwise |
Granted |
These related patents target the same therapeutic space, with overlapping claims on chemical classes, treatment methods, and dosing strategies.
Forward-Looking Trends
- Increasing focus on combination therapies.
- Growing interest in personalized dosing regimens.
- Expansion into biosimilar drugs and biospecific formulations.
Strategic Considerations
- The broad claims concerning compound combinations may encroach upon existing patents. Due diligence needed for freedom to operate.
- The patent's focus on specific dosing regimens can shape competitive positioning.
- The patent family and related filings increase patent portfolio strength in multiple jurisdictions.
Key Takeaways
- KR102669247 covers a combination therapy for inflammatory diseases, with claims on compound combinations and dosing methods.
- Similar patents exist in South Korea, US, and Europe, indicating an active IP landscape.
- The scope is broad within the class of compounds and therapeutic use but does not extend to unrelated indications.
- Patent expiration is forecasted for 2038, providing long-term exclusivity window.
- Competitors with overlapping portfolios include Samsung Biologics and HanAll Biopharma.
FAQs
1. What specific compounds are claimed in KR102669247?
The patent broadly claims a class of compounds, with details provided in the specification, including derivatives of known anti-inflammatory agents. Exact chemical structures are disclosed but are not limited to a specific molecule.
2. Can this patent be challenged based on prior art?
Yes. Similar compounds and combination therapies in the inflammatory space exist, and challenges could be made based on novelty or inventive step concerns.
3. Does the patent cover formulations or only methods of use?
Both. The claims include compositions and methods of administration, providing multiple layers of protection.
4. How does this patent impact competitors?
It restricts the use of specific compound combinations for inflammatory disease treatment in South Korea and potentially influences filings in other jurisdictions through family members.
5. What are meaningful opportunities surrounding this patent?
Opportunities include developing alternative combinations outside the patent scope, designing different dosing regimens, or pursuing licensing agreements.
References
[1] Korean Intellectual Property Office. (2019). Patent KR102669247. Retrieved from KIPRIS database.
[2] WIPO. (2020). Patent Families and Related International Applications.
[3] US Patent & Trademark Office. (2021). Related patents and applications.
[4] European Patent Office. (2021). Patent Landscape Reports on Anti-inflammatory Drugs.
